Effect of a phytopharmaceutical medicine, Ginko biloba extract 761, in an animal model of Parkinson's disease: Therapeutic perspectives

Nutrition

Volumn 28, Issue 11-12, 2012, Pages 1081-1088

  Rojas, Patricia ^a   Montes, Pedro ^a   Rojas, Carolina ^b   Serrano García, Norma ^a   Rojas Castañeda, Julio César ^c  

^a NATIONAL INSTITUTE OF NEUROLOGY AND NEUROSURGERY   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^c INSTITUTO NACIONAL DE PEDIATRÍA   (Mexico)

Author keywords

Antioxidant; Dopamine; Natural extract; Neuroprotection; Recovery

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; FLAVONOID; GINKGO BILOBA EXTRACT; GINKGOLIDE B; ICOSANOID; INTERLEUKIN 1; LEUKOTRIENE; LEVODOPA; REACTIVE OXYGEN METABOLITE; SELEGILINE; SUPEROXIDE DISMUTASE; TERPENOID DERIVATIVE; THROMBOCYTE ACTIVATING FACTOR; THROMBOXANE B2; TUMOR NECROSIS FACTOR ALPHA;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; BLOOD PRESSURE; CHEMICAL COMPOSITION; DIZZINESS; DOPAMINE METABOLISM; DOPAMINE UPTAKE; DOPAMINERGIC NERVE CELL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; GINKGO BILOBA; HEART RATE; HUMAN; LIPID OXIDATION; MAXIMUM PLASMA CONCENTRATION; MULTIINFARCT DEMENTIA; NAUSEA; NERVE DEGENERATION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TINNITUS; VERTIGO; VOMITING;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIOXIDANTS; ANTIPARKINSON AGENTS; APOPTOSIS; DIETARY SUPPLEMENTS; DISEASE MODELS, ANIMAL; DOPAMINERGIC NEURONS; HUMANS; MESENCEPHALON; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; PARKINSON DISEASE; PHYTOTHERAPY; PLANT EXTRACTS;

ANIMALIA; GINKGO (GENUS); GINKGO BILOBA;

EID: 84867190953     PISSN: 08999007     EISSN: 18731244     Source Type: Journal    
DOI: 10.1016/j.nut.2012.03.007     Document Type: Review

References (91)

1. Droy-Lefaix M.T., Cluzel J., Menerath J.M., Bonhomme B., Doly M. Antioxidant effect of a Ginkgo biloba extract (EGb761) on the retina. Int J Tissue React 1995, 17:93-100.
2. Maitra I., Marcocci L., Droy-Lefaix M.T., Packer L. Peroxyl radical scavenging activity of Ginkgo biloba extract EGb 761. Biochem Pharmacol 1995, 49:1649-1655.
3. Ni Y., Zhao B., Hou J., Xin W. Preventive effect of Ginkgo biloba extract on apoptosis in rat cerebellar neuronal cells induced by hydroxyl radicals. Neurosci Lett 1996, 214:115-118.
4. Rojas P., Serrano-García N., Mares-Sámano J.J., Medina-Campos O.N., Pedraza-Chaverri J., Ogren S.O. EGb 761 protects against nigrostriatal dopaminergic neurotoxicity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice: role of oxidative stress. Eur J Neurosci 2008, 28:41-50.
5. DeFeudis F.V., Drieu K. Ginkgo biloba extract (EGb 761) and CNS functions: basic studies and clinical applications. Curr Drug Targets 2000, 1:25-28.
6. Gerlach M., Ben-Shachar D., Riederer P., Youdim M.B. Altered brain metabolism of iron as a cause of neurodegenerative diseases?. J Neurochem 1994, 63:793-807.
7. Jenner P., Olanow C.W. Oxidative stress and the pathogenesis of Parkinson's disease. Neurology 1996, 47(suppl 3):S161-S170.
8. Dexter D.T., Holley A.E., Flitter W.D., Slater T.F., Wells F.R., Daniel S.E., et al. Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra: an HPLC and ESR study. Mov Disord 1994, 9:92-97.
9. Zhang J., Perry G., Smith M.A., Robertson D., Olson S.J., Graham D.G., Montine T.J. Parkinson's disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons. Am J Pathol 1999, 154:1423-1429.
10. Yao Z., Wood N.W. Cell death pathways in Parkinson's disease: role of mitochondria. Antioxid Redox Signal 2009, 11:2135-2149.
11. Perier C., Bové J., Vila M. Mitochondria and programmed cell death in Parkinson's disease: apoptosis and beyond. Antioxid Redox Signal 2012, 16:883-895.
12. DeFeudis F.V. Ginkgo biloba extract (EGb761): from chemistry to the clinic 1998, Ullstein Medical, Wiesbaden, Germany. 1st ed.
13. Drieu K. Preparation and definition of G. biloba extract. Press Med 1986, 15:1455-1457.
14. Kleijnen J., Knipschild P. Ginkgo biloba. Lancet 1992, 340:1136-1139.
15. Bilia A.R. Ginkgo biloba L. Fitoterapia 2002, 73:276-279.
16. Diamond B.J., Shiflett S.C., Feiwel N., Matheis R.J., Noskin O., Richards J.A., Schoenberger N.E. Ginkgo biloba extract: mechanisms and clinical indications. Arch Phys Med Rehabil 2000, 81:668-678.
17. +-induced lipid peroxidation in mouse corpus striatum. Neurochem Res 2001, 26:1245-1251.
18. Ernst E. The risk-benefit profile of commonly used herbal therapies: Ginkgo, St John's wort, ginseng, Echinacea, saw palmetto and kawa. Ann Intern Med 2002, 136:42-53.
19. Tansey M.G., Goldberg M.S. Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention. Neurobiol Dis 2010, 37:510-518.
20. Chan L.W., Wang Y.Q., Wei L.C., Shi M., Chan Y.S. Chinese herbs and herbal extracts for neuroprotection of dopaminergic neurons and potential therapeutic treatment of Parkinson's disease. CNS Neurol Disord Drug Targets 2007, 6:273-281.
21. Hynes N., Bishai I., Lees J., Coceani F. Leukotrienes in brain: natural occurrence and induced changes. Brain Res 1991, 553:4-13.
22. Kunievsky B., Yavin E. Platelet-activating factor stimulates arachidonic acid release and enhances thromboxane B2 production in intact fetal rat brain ex vivo. J Pharmacol Exp Ther 1992, 263:562-568.
23. Shi C., Zhao L., Zhu B., Li Q., Yew D.T., Yao Z., Xu J. Dosage effects of EGb761 on hydrogen peroxide-induced cell death in SH-Sy5Y cells. Chem Biol Interact 2009, 180:389-397.
24. Du Z.Y., Li X.Y. Effects of ginkgolides on interleukin-1, tumor necrosis factor-alpha and nitric oxide production by rat microglia stimulated with lipopolysaccharides in vitro. Arzneim Forsch 1998, 48:1126-1130.
25. Marcocci L., Packer L., Droy-Lefaix M., Sekaki A., Gardes-Albert M. Antioxidant action of Ginkgo biloba extract EGb 761. Methods Enzymol 1994, 234:462-475.
26. Gardés-Albert M., Ferradini C., Sekaki A., Droy-LeFaix M.T. Oxygen-centered free radicals and their interactions with EGb 761 or CP 202. Advances in Ginkgo biloba extract research, Volume 2. Ginkgo biloba extract (EGb 761) as a free radical scavenger 1993, 1-11. Elsevier, Paris. C. Ferradini, M.T. Droy-LeFaix, C. Christen (Eds.).
27. Saija A., Scalese M., Lanza M., Marzullo D., Bonina F., Castelli F. Flavonoids as antioxidant agents: importance of their interaction with biomembranes. Free Radic Biol Med 1995, 19:481-486.
28. Shi C., Zhao L., Zhu B., Li Q., Yew D.T., Yao Z., et al. Protective effects of Ginkgo biloba extract (EGb761) and its constituents quercetin and ginkgolide B against beta-amyloid peptide-induced toxicity in SH-SY5Y cells. Chem Biol Interact 2009, 181:115-123.
29. Sastre J., Millán A., García J., Plá R., Juan G., Pallardó F.V., et al. A Ginkgo biloba extract (EGb 761) prevents mitochondrial aging by protecting against oxidative stress. Free Radic Biol Med 1998, 24:298-304.
30. Bridi R., Crossetti F.P., Steffen V.M., Henriques A.T. The antioxidant activity of standardized extract of Ginkgo biloba (EGb 761) in rats. Phytother Res 2001, 15:449-451.
31. Pardon M.C., Joubert C., Perez-Diaz F., Christen Y., Launay J.M., Cohen-Salmon C. In vivo regulation of cerebral monoamine oxidase activity in senescent controls and chronically stressed mice by long-term treatment with Ginkgo biloba extract (EGb 761). Mech Ageing Dev 2000, 113:157-168.
32. Eckert A., Keil U., Kressmann S., Schindowski K., Leutner S., Leutz S., et al. Effects of EGb 761 Ginkgo biloba extract on mitochondrial function and oxidative stress. Pharmacopsychiatry 2003, 36:S15-S23.
33. Winter J.C. The effects of an extract of Ginkgo biloba, 761, on cognitive behavior on longevity in the rat. Physyiol Behav 1998, 63:425-433.
34. Liu T.J., Yeh Y.C., Ting C.T., Le W.L., Wang L.C., Lee H.W., et al. Ginkgo biloba extract 761 reduced doxorubicin-induced apoptotic damage in rat hearts and neonatal cardiomyocytes. Cardiovasc Res 2008, 80:227-235.
35. Yeh Y.C., Liu T.J., Wang L.C., Lee H.W., Ting C.T., Lee W.L., et al. A standardized extract of Ginkgo biloba suppresses doxorubicin-induced oxidative stress and p53-mediated mitochondrial apoptosis in rat testes. Br J Pharmacol 2009, 156:48-61.
36. Nevado J., Sanz R., Sánchez-Rodríguez C., García-Berrocal J.R., Martín-Sanz E., González-García J.A., et al. Ginkgo biloba extract (EGb 761) protects against aging-related caspase-mediated apoptosis in rat cochlea. Acta Otolaryngol 2010, 130:1101-1112.
37. Lu G., Wu Y., Mak Y.T., Wai S.M., Feng Z.T., Rudd J.A., Yew D.T. Molecular evidence of the neuroprotective effect of Ginkgo biloba (EGb 761) using bax/bcl-2 ratio after brain ischemia in senescence-accelerated mice, strain prone-8. Brain Res 2006, 1090:23-28.
38. L interaction following cerebral ischemia. Am J Chin Med 2009, 37:867-876.
39. Li S., Tang D., Xue Z., Zhang Z., Sun X., Liu Y., et al. Biphasic effect of EGb 761 on simulated ischemia-induced rat BMSC survival in vitro and in vivo. Life Sci 2011, 88:853-863.
40. Lim S., Yoon W.J., Kang S.K., Choi S.C., Cho B.J., Kim M., et al. EGb761, a Ginkgo biloba extract, is effective against atherosclerosis in votro, and in a rat model of type 2 diabetes. PloS ONE 2011, 6:1-9.
41. Wang J., Cheng Y., Yin J., Lu Q., Xu X., Yin X. Protective effects of Ginkgo biloba extract on 6-hydroxydopamine-induced apoptosis in PC12 cells. Neural Regeneration Res 2011, 6:2565-2572.
42. Kang X., Chen J., Xu Z., Li H., Wang B. Protective effects of Ginkgo biloba extract on paraquat-induced apoptosis of PC12 cells. Toxicol In Vitro 2007, 21:1003-1009.
43. Yang S.F., Wu Q., Sun A.S., Huang X.N., Shi J.S. Protective effect and mechanism of Ginkgo biloba leaf extracts for Parkinson disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Acta Pharmacol Sin 2001, 22:1089-1093.
44. Tsang A.H., Chung K.K. Oxidative and nitrosative stress in Parkinson's disease. Biochim Biophys Acta 2009, 1792:643-660.
45. Halliwell B. Free radicals and antioxidants-quo vadis?. Trends Pharmacol Sci 2011, 32:125-130.
46. Danielson S.R., Andersen J.K. Oxidative and nitrative protein modifications in Parkinson's disease. Free Radic Biol Med 2008, 44:1787-1794.
47. Andersen J.K. Oxidative stress in neurodegeneration: cause or consequence?. Nat Med 2004, 10:S18-S25.
48. Lenaz G., Bovina C., D'Aurelio M., Fato R., Formiggini G., Genova M.L., et al. Role of mitochondria in oxidative stress and aging. Ann N Y Acad Sci 2002, 959:199-213.
49. McLennan H.R., Degli Esposti M. The contribution of mitochondrial respiratory complexes to the production of reactive oxygen species. J Bioenerg Biomembr 2000, 32:153-162.
50. Sayre L.M., Perry G., Smith M.A. Oxidative stress and neurotoxicity. Chem Res Toxicol 2008, 21:172-188.
51. Hussain S., Slikker W., Ali S.F. Age related changes in antioxidant enzymes, superoxide dismutase, catalase, glutathione peroxidase and glutathione in different regions of mouse brain. Int J Dev Neurosci 1995, 13:811-817.
52. Dexter D.T., Carter C.J., Wells F.R., Javoy-Agid F., Agid Y., Leesz A., et al. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem 1989, 52:381-389.
53. Yoritaka A., Hattori N., Uchida K., Tanaka M., Stadtman E.R., Mizuno Y. Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. Proc Natl Acad Sci U S A 1996, 93:2696-2701.
54. Floor E., Wetzel M.G. Increased protein oxidation in human substantia nigra pars compacta in comparison with basal ganglia and prefrontal cortex measured with an improved dinitrophenylhydrazine assay. J Neurochem 1998, 70:268-275.
55. Nakabeppu Y., Tsuchimoto D., Yamaguchi H., Sakumi K. Oxidative damage in nucleic acids and Parkinson's disease. J Neurosci Res 2007, 85:919-934.
56. Bender A., Krishnan K.J., Morris C.M., Taylor G.A., Reeve A.K., Perry R.H., et al. High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease. Nat Gene 2006, 38:515-517.
57. Saggu H., Cooksey J., Dexter D., Wells F.R., Lees A., Jenner P., et al. A selective increase in particulate superoxide dismutase activity in parkinsonian substantia nigra. J Neurochem 1989, 53:692-697.
58. Amnabi L.M., Van Woert M.H., Murphy S. Brain peroxidase and catalase in Parkinson's disease. Arch Neurol 1975, 32:114-118.
59. Cohen G. Monoamine oxidase, hydrogen peroxide, and Parkinson's disease. Advances in neurology: Parkinson's disease 1986, 119-125. Raven Press, New York. M.D. Yahr, K.J. Bergmann (Eds.).
60. Riederer P., Jellinger K. Neurochemical insights into monoamine oxidase inhibitors, with special reference to deprenyl (selegiline). Acta Neurol Scand Suppl 1983, 95:43-55.
61. Knoll J. Rationale for (-) deprenyl (selegiline) medication in Parkinson's disease and in prevention of age-related nigral changes. Biomed Pharmacother 1995, 49:187-195.
62. Schapira A.H., Jenner P. Etiology and pathogenesis of Parkinson's disease. Mov Disord 2011, 26:1049-1055.
63. Lipski J., Nistico R., Berretta N., Guatteo E., Bernardi G., Mercuri N.B. L-DOPA: a scapegoat for accelerated neurodegeneration in Parkinson's disease?. Prog Neurobiol 2011, 94:389-407.
64. Müller T. Motor complications, levodopa metabolism and progression of Parkinson's disease. Expert Opin Drug Metab Toxicol 2011, 7:847-855.
65. Gerlach M., Riederer P., Przuntek H., Youdim M.B.H. MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease. Eur J Pharmacol Mol Pharmacol 1991, 208:273-286.
66. Przedborski S., Jackson-Lewis V., Djaldetti R., Liberatore G., Vila M., Vukosavic S., et al. The parkinsonian toxin MPTP: action and mechanism. Restor Neurol Neurosci 2000, 16:135-142.
67. Zang L.Y., Misra H.P. Generation of reactive oxygen species during the monoamine oxidase-catalyzed oxidation of the neurotoxicant, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. J Biol Chem 1993, 268:16504-16512.
68. Adams J.D., Klaidman L.K., Leung A. MPP+ and MPDP+ induced oxygen radical formation with mitochondrial enzymes. Free Radic Biol Med 1993, 15:181-186.
69. Wong S.S., Li R.H., Stadlin A. Oxidative stress induced by MPTP and MPP(+): selective vulnerability of cultured mouse astrocytes. Brain Res 1999, 836:237-244.
70. Yurek D.M., Deutch A.Y., Roth R.H., Sladek J.R. Morphological, neurochemical, and behavioral characterizations associated with the combined treatment of diethyldithiocarbamate and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. Brain Res 1989, 497:250-259.
71. Przedborski S., Kostic V., Jackson-Lewis V., Naini A.B., Simonetti S., Fahn S., et al. Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity. J Neurosci 1992, 12:1658-1667.
72. + administration to mice. Pharmacol Toxicol 1993, 72:364-368.
73. Park S.W., Kim S.H., Park K.H., Kim S.D., Kim J.Y., Baek S.Y., et al. Preventive effect of antioxidants in MPTP-induced mouse model of Parkinson's disease. Neurosci Lett 2004, 363:243-246.
74. Ramassamy C., Girbe F., Christen Y., Costentin J. Ginkgo biloba extract EGb 761 or trolox C prevent the ascorbic ac id/Fe 2+ induced decrease in synaptosomal membrane fluidity. Free Radic Res Commun 1993, 19:341-350.
75. Ahmad M., Saleem S., Ahmad A.S., Yousuf S., Ansari M.A., Khan M.B., et al. Ginkgo biloba affords dose-dependent protection against 6-hydroxydopamine-induced parkinsonism in rats: neurobehavioural, neurochemical and immunohistochemical evidences. J Neurochem 2005, 93:94-104.
76. Kang X., Chen J., Xu Z., Li H., Wang B. Protective effects of Ginkgo biloba extract on paraquat-induced apoptosis of PC12 cells. Toxicol In Vitro 2007, 21:1003-1009.
77. Kim M.S., Lee J.I., Lee W.Y., Kim S.E. Neuroprotective effect of Ginkgo biloba L. extract in a rat model of Parkinson's disease. Phytother Res 2004, 18:663-666.
78. Rafalowska U., Liu G.J., Floy R.A. Peroxidation induced changes in synaptosomal transport of dopamine and gamma-aminobutyric acid. Free Radic Biol Med 1989, 6:485-492.
79. Ramassamy C., Naudin B., Christen Y., Clostre F., Costentin J. Prevention by Ginkgo biloba extract (EGb 761) and trolox C of the decrease in synaptosomal dopamine or serotonin uptake following incubation. Biochem Pharmacol 1992, 44:2395-2401.
80. Nagatsu T., Sawada M. Molecular mechanism of the relation of monoamine oxidase B and its inhibitors to Parkinson's disease: possible implications of glial cells. J Neural Transm Suppl 2006, 71:53-65.
81. Wu W.R., Zhu X.Z. Involvement of monoamine oxidase inhibition in neuroprotective and restorative effects of Ginkgo biloba extract against MPTP-induced nigrostriatal dopaminergic toxicity in C-57 mice. Life Sci 1999, 65:157-164.
82. Rojas P., Rojas C., Ebadi M., Montes S., Monroy-Noyola A., Serrano-García N. EGb 761 pretreatment reduces monoamine oxidase activity in mouse corpus striatum during 1-methyl-4-phenylpyridinium neurotoxicity. Neurochem Res 2004, 29:1417-1423.
83. Ramassamy C., Clostre F., Christen Y., Costentin J. Prevention by a Ginkgo biloba extract (EGB 761) of the dopaminergic neurotoxicity of MPTP. J Pharm Pharmacol 1990, 42:785-789.
84. Melega W.P., Cho A.K., Schmitz D., Kuczenski R., Segal D.S. L-amphetamine pharmacokinetics and pharmacodynamics for assessment of in vivo deprenyl-derived L-amphetamine. J Pharmacol Exp Ther 1999, 288:752-758.
85. Mattson M.P. Modification of ion homeostasis by lipid peroxidation: roles in neuronal degeneration and adaptive plasticity. Trends Neurosci 1998, 21:53-57.
86. Rimbach G., Gohil K., Matsugo S., Moini H., Saliou C., Virgili F., et al. Induction of glutathione synthesis in human keratinocytes by Ginkgo biloba extract (EGb761). Biofactors 2001, 15:39-52.
87. Sasaki K., Hatta S., Wada K., Ueda N., Yoshimura T., Endo T., et al. Effects of extract of Ginkgo biloba leaves and its constituents on carcinogen-metabolizing enzyme activities and glutathione levels in mouse liver. Life Sci 2002, 70:1657-1667.
88. Lacour M., Ez-Zaher L., Raymond J. Plasticity mechanisms in vestibular compensation in the cat are improved by an extract of Ginkgo biloba (EGb 761). Pharmacol Biochem Behav 1991, 40:367-379.
89. Schwarting R.K., Huston J.P. The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments. Prog Neurobiol 1996, 50:275-331.
90. Gohil K., Packer L. Global gene expression analysis identifies cell and tissue specific actions of Ginkgo biloba extract, EGb 761. Cell Mol Biol 2002, 48:625-631.
91. Cao F., Sun S., Tong E.T. Experimental study on inhibition of neuronal toxical effect of levodopa by ginkgo biloba extract on Parkinson disease in rats. J Huazhong Univ Sci Technol Med Sci 2003, 23:151-153.